First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial - Takeaways - MDSpire

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • By

  • Peter Schmid

  • Seock-Ah Im

  • Zbigniew Nowecki

  • Piotr J. Wysocki

  • Jacek Jassem

  • Kyung Hae Jung

  • Simon Lord

  • Jon Armstrong

  • Ross Stewart

  • Petra Vuković

  • Neelima Denduluri

  • Yeon Hee Park

  • June 8, 2026

  • 0 min

Share

  • 1

    The BEGONIA trial evaluated durvalumab combined with trastuzumab deruxtecan for HR-negative, HER2-low breast cancer.

  • 2

    58 participants were enrolled, with a median age of 54 years and a majority having PD-L1-negative tumors.

  • 3

    The confirmed objective response rate was 62.1%, with one complete response and 35 partial responses among participants.

  • 4

    Most participants discontinued treatment due to disease progression, with 77.6% stopping durvalumab and 81.0% stopping T-DXd.

  • 5

    The trial's findings suggest potential efficacy of the combination therapy in a challenging breast cancer subtype.

Original Source(s)

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • by Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J. Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

  • June 8, 2026

Related Content

Value of point-of-care ultrasound in the early identification of left ventricular dysfunction and prognostic assessment in cancer patients complicated by sepsis

Case Report: a rare case of small cell carcinoma of the prostate

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies